DEXCOM INC（DXCM）の決算・業績分析
DEXCOM INCの2025年有価証券報告書をAI分析。売上高$4.7B(+15.6%)。営業利益$912M。Health Care。
目次
DEXCOM INCの2025年度 業績サマリー
DEXCOM INC（証券コード: DXCM）の2025年度決算・業績分析。売上高は$4.7B（前年比+15.6%）。営業利益は$912M（前年比+52.0%）。純利益は$836M（前年比+45.1%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
DEXCOM INCの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- Revenue surged to $2.9B (+18.8% YoY) driven by product launches (G6, G7, Stelo) and global expansion (XBRL).
- Net income jumped 57.3% YoY to $341M, with operating income rising 47.2% to $391M (XBRL).
- Gross margin remained robust at 64.7%, supported by operational efficiencies (XBRL).
- Cash reserves reached $642M, with $558M returned to shareholders via share repurchases (XBRL).
- 5-year revenue CAGR of 28.6% underscores sustained growth in the CGM market (XBRL).
DEXCOM INCの売上高変化の要因
- •Total revenue reached $2.9B in FY2024, reflecting +18.8% YoY growth (XBRL). The 5-year revenue CAGR of 28.6% highlights consistent expansion, with revenue increasing from $1.0B in FY2020 to $2.9B in FY2024 (Historical Time Series). Growth drivers include product launches (G6, G7, Stelo) and global market penetration (10-K). No segment-specific revenue data is available (N/A).
DEXCOM INCの営業利益変化の要因
- •Gross profit was $1.9B with a 64.7% margin (XBRL), up from FY2023's $1.9B (no YoY change specified). Operating income rose 47.2% YoY to $391M, driven by product innovation and efficiency gains (XBRL). Net income increased 57.3% YoY to $341M, with net margin at 11.7% (XBRL). R&D expenses totaled $484M, reflecting heavy investment in future technologies (XBRL).
DEXCOM INCの事業リスクと対応
Pricing pressure from third-party payors may reduce product prices and reimbursement rates, harming revenue and profitability (10-K).
Inadequate coverage or reimbursement policies could limit patient access and reduce demand for products (10-K).
Regulatory hurdles with Medicare and other payors may restrict reimbursement to specific patient subsets (10-K).
CMS coverage criteria changes could impact Medicare reimbursement for CGM systems (10-K).
Administrative challenges in obtaining coverage from payors may delay or reduce product adoption (10-K).
DEXCOM INCの今後の見通し・業績予想
DEXCOM INCの事業内容
DEXCOM INC (DXCM) is a medical device company specializing in continuous glucose monitoring (CGM) systems for diabetes and metabolic health management (10-K). Its core products include the FDA-cleared Dexcom G7 (8.2% MARD accuracy), Dexcom G6 (first integrated CGM with automated insulin delivery compatibility), and Stelo (over-the-counter biosensor for prediabetes/Type 2 diabetes) (10-K). The company generates revenue through the sale of these CGM systems, leveraging clinical accuracy, digital health integration (e.g., Apple Watch, insulin pumps), and innovative features like 10-day sensors (10-K). No explicit business segments are disclosed in the data.
DEXCOM INCのAI業績分析レポート（2024年度）
DEXCOM INC (DXCM) FY2024 Annual Report Analysis
Highlights
Business Overview
DEXCOM INC (DXCM) is a medical device company specializing in continuous glucose monitoring (CGM) systems for diabetes and metabolic health management (10-K). Its core products include the FDA-cleared Dexcom G7 (8.2% MARD accuracy), Dexcom G6 (first integrated CGM with automated insulin delivery compatibility), and Stelo (over-the-counter biosensor for prediabetes/Type 2 diabetes) (10-K). The company generates revenue through the sale of these CGM systems, leveraging clinical accuracy, digital health integration (e.g., Apple Watch, insulin pumps), and innovative features like 10-day sensors (10-K). No explicit business segments are disclosed in the data.
Revenue Analysis
Total revenue reached $2.9B in FY2024, reflecting +18.8% YoY growth (XBRL). The 5-year revenue CAGR of 28.6% highlights consistent expansion, with revenue increasing from $1.0B in FY2020 to $2.9B in FY2024 (Historical Time Series). Growth drivers include product launches (G6, G7, Stelo) and global market penetration (10-K). No segment-specific revenue data is available (N/A).
Profitability Analysis
Gross profit was $1.9B with a 64.7% margin (XBRL), up from FY2023's $1.9B (no YoY change specified). Operating income rose 47.2% YoY to $391M, driven by product innovation and efficiency gains (XBRL). Net income increased 57.3% YoY to $341M, with net margin at 11.7% (XBRL). R&D expenses totaled $484M, reflecting heavy investment in future technologies (XBRL).
Balance Sheet Analysis
Total assets grew from $2.4B in FY2020 to $6.3B in FY2024 (Historical Time Series). Equity increased from $419M in FY2020 to $2.0B in FY2024, with an equity ratio of 32.6% (XBRL). Cash reserves stood at $642M (XBRL). The debt-to-equity ratio was 2.05x (XBRL), and the current ratio was 2.84x (XBRL).
Cash Flow Analysis
Operating cash flow reached $670M (XBRL), up from $442M in FY2023. Free cash flow (FCF) was $305M, calculated as $670M operating cash flow minus $365M CapEx (XBRL). Investing cash flow was -$522M, primarily from CapEx. Financing cash flow was -$552M, driven by $558M in share repurchases (XBRL). No dividends were reported (N/A).
Working Capital Analysis
Receivables days were 122 days, and inventory days were 199 days (XBRL). Payables days and cash conversion cycle (CCC) data are not available (N/A). Asset turnover was 0.46x (XBRL).
Risks
Outlook
Management expects continued growth from product launches (G7, Stelo) and partnerships with insulin pump companies (10-K). Key trends include expansion into new markets (prediabetes, obesity) and innovation in digital health integration (10-K). No specific financial guidance was provided (N/A).
Health Careの企業一覧
DEXCOM INCと同じ「Health Care」セクターの企業